Hakan Kocoglu
Research Subjects
Research Interests
Hakan Kocoglu has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Ozlem Harmankaya
13 shared publicationsYildiz Okuturlar
13 shared publications- Yildiz Okuturlar
Acibadem University, school of medicine
12 shared publications - Mehmet Hursitoglu
Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
10 shared publications - Abdulbaki Kumbasar
Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
9 shared publications Meral Gunaldi
Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
8 shared publications
Latest Publications
- Open Access
- 30 April 2024
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 8 (1) , 39-44
Effect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19
Aim:During the ongoing COVID-19 pandemic, the management of hyperinflammation, a serious symptom that occurs secondary to the disease, has emerged as a major challenge. Tocilizumab, an immunosuppressive drug, offers a potential solution. However, it is extremely important to understand its effects on antibody formation after recovery from Covid-19. Therefore, our study aimed to investigate the effects of tocilizumab treatment on antibody production by measuring SARS-COV-2 spike total antibody levels at the third month post-infection in patients receiving this specific treatment. Materyal and Methods:Our study incorporated 48 patients diagnosed with Covid 19 who presented with hyperinflammation during hospitalization. These patients, admitted to our institution, were treated with tocilizumab and subsequently discharged. We meticulously determined the 3rd month SARS-COV-2 spike total antibody levels in these patients. Results:The participants of the study, characterized by a mean age of 52.5 ± 11.6 years, demonstrated positive SARS-COV-2 spike total antibody levels at 3 months, irrespective of age, gender, comorbidity, and length of hospital stay. The mean antibody levels in the patient population were quantified to be 223.58 ± 68.36 U/mL, with a range from 14.2 to 250 U/mL. Conclusion: Our findings reveal that all patients exhibited positive antibody levels at 3 months following tocilizumab treatment.This suggests that the administration of tocilizumab in the management of hyperinflammation secondary to Covid 19 does not adversely affect antibody formation, at least in the short term. This could have substantial implications for future treatment strategies.
- 30 April 2024
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 8 (1) , 39-44
Open AccessEffect of Tocilizumab Treatment on Seroconversion in Hyperinflammation Secondary to Covid 19
Aim:During the ongoing COVID-19 pandemic, the management of hyperinflammation, a serious symptom that occurs secondary to the disease, has emerged as a major challenge. Tocilizumab, an immunosuppressive drug, offers a potential solution. However, it is extremely important to understand its effects on antibody formation after recovery from Covid-19. Therefore, our study aimed to investigate the effects of tocilizumab treatment on antibody production by measuring SARS-COV-2 spike total antibody levels at the third month post-infection in patients receiving this specific treatment. Materyal and Methods:Our study incorporated 48 patients diagnosed with Covid 19 who presented with hyperinflammation during hospitalization. These patients, admitted to our institution, were treated with tocilizumab and subsequently discharged. We meticulously determined the 3rd month SARS-COV-2 spike total antibody levels in these patients. Results:The participants of the study, characterized by a mean age of 52.5 ± 11.6 years, demonstrated positive SARS-COV-2 spike total antibody levels at 3 months, irrespective of age, gender, comorbidity, and length of hospital stay. The mean antibody levels in the patient population were quantified to be 223.58 ± 68.36 U/mL, with a range from 14.2 to 250 U/mL. Conclusion: Our findings reveal that all patients exhibited positive antibody levels at 3 months following tocilizumab treatment.This suggests that the administration of tocilizumab in the management of hyperinflammation secondary to Covid 19 does not adversely affect antibody formation, at least in the short term. This could have substantial implications for future treatment strategies.
- Open Access
- 21 December 2021
- Published by Springer Nature in Research Square
Metformin significantly lowers the mortality rate in diabetic COVID-19 patients
Introduction: This study evaluates the effect of glycemic control and anti-diabetic agents on the prognosis of diabetic COVID-19 patients. Method: The study includes diabetic patients who were treated and followed up in our hospital because of COVID-19 between 1 June 2020 and 1 January 2021. Patients with any additional comorbidity were excluded from the study. The demographic data of the patients, physical examination findings, laboratory tests, and radiological examination results were obtained retrospectively from the hospital records system.Results: A total of 207 diabetic patients consisted of 125 (60.4%) males and 82 (39.6%) females were included to this study. The mortality rate in cases using metformin was found to be statistically significantly lower than in cases using other drugs (p=0.016; p0.05).Discussion: Metformin treatment in diabetic patients diagnosed with COVID-19 should not be stopped, other than in cases with severely hypoxic advanced stage chronic renal failure. Metformin can be recommended as a preventative drug to increase survival in diabetic patients with COVID-19. Nevertheless, there is a need for more evidence and more extensive studies to investigate the protective effects of metformin in COVID-19 patients and in similar viral infections.
- 21 December 2021
- Published by Springer Nature in Research Square
Open AccessMetformin significantly lowers the mortality rate in diabetic COVID-19 patients
Introduction: This study evaluates the effect of glycemic control and anti-diabetic agents on the prognosis of diabetic COVID-19 patients. Method: The study includes diabetic patients who were treated and followed up in our hospital because of COVID-19 between 1 June 2020 and 1 January 2021. Patients with any additional comorbidity were excluded from the study. The demographic data of the patients, physical examination findings, laboratory tests, and radiological examination results were obtained retrospectively from the hospital records system.Results: A total of 207 diabetic patients consisted of 125 (60.4%) males and 82 (39.6%) females were included to this study. The mortality rate in cases using metformin was found to be statistically significantly lower than in cases using other drugs (p=0.016; p0.05).Discussion: Metformin treatment in diabetic patients diagnosed with COVID-19 should not be stopped, other than in cases with severely hypoxic advanced stage chronic renal failure. Metformin can be recommended as a preventative drug to increase survival in diabetic patients with COVID-19. Nevertheless, there is a need for more evidence and more extensive studies to investigate the protective effects of metformin in COVID-19 patients and in similar viral infections.
- Open Access
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 53 (2) , 85-89
The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus
Objective: The prevalence of diabetes mellitus is growing worldwide, as well as in the aging population, and its comorbidity and mortality rates are higher in aging people than they are in young people. It has been observed that the number of drugs used increases in aging patients, especially in diabetic patients. This study aimed to investigate the relationship between polypharmacy and modified Charlson Comorbidity Index (CCI) and Katz Index of Independence in Activities of Daily Living (Katz ADL) scores in aging diabetic and non-diabetic patients. Materials and Methods: This prospective study included 184 diabetic and 62 non-diabetic subjects who were ≥65 years old. Comorbidity was determined with CCI, and dependency on daily basic activities was assessed with Katz ADL. Results: CCI and the number of drugs were significantly higher in diabetic groups (P = .001). In all subjects and in the diabetic group, there was a negative correlation between CCI and Katz ADL (r = −0.343, P = .001; r = −0.383, P = .001, respectively); there was a positive correlation between CCI and number of drugs (r = 0.430, P = .001; r = 0.248, P = .001, respectively). Conclusion: We found an increase in the number of drugs taken by the aging patients, positively correlated with the CCI score. The increase in the number of drugs used is closely related to the insufficiency in daily life activity and comorbidity, and this predicts 10-year survival. Patients should be directed to special centers or physicians who will be scheduled for multidisciplinary treatment for the prevention of polypharmacy, especially in the aging. Cite this article as: Sahingoz Erdal G, Kocoglu H, Karandere F, Kasapoglu P, Isiksacan NN, Hursitoglu M. The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus. Eurasian J Med 2021; 53(2): 85-9.
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 53 (2) , 85-89
Open AccessThe Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus
Objective: The prevalence of diabetes mellitus is growing worldwide, as well as in the aging population, and its comorbidity and mortality rates are higher in aging people than they are in young people. It has been observed that the number of drugs used increases in aging patients, especially in diabetic patients. This study aimed to investigate the relationship between polypharmacy and modified Charlson Comorbidity Index (CCI) and Katz Index of Independence in Activities of Daily Living (Katz ADL) scores in aging diabetic and non-diabetic patients. Materials and Methods: This prospective study included 184 diabetic and 62 non-diabetic subjects who were ≥65 years old. Comorbidity was determined with CCI, and dependency on daily basic activities was assessed with Katz ADL. Results: CCI and the number of drugs were significantly higher in diabetic groups (P = .001). In all subjects and in the diabetic group, there was a negative correlation between CCI and Katz ADL (r = −0.343, P = .001; r = −0.383, P = .001, respectively); there was a positive correlation between CCI and number of drugs (r = 0.430, P = .001; r = 0.248, P = .001, respectively). Conclusion: We found an increase in the number of drugs taken by the aging patients, positively correlated with the CCI score. The increase in the number of drugs used is closely related to the insufficiency in daily life activity and comorbidity, and this predicts 10-year survival. Patients should be directed to special centers or physicians who will be scheduled for multidisciplinary treatment for the prevention of polypharmacy, especially in the aging. Cite this article as: Sahingoz Erdal G, Kocoglu H, Karandere F, Kasapoglu P, Isiksacan NN, Hursitoglu M. The Effect of Polypharmacy on the Charlson Comorbidity Index and Katz Index in Aging People with and without Diabetes Mellitus. Eurasian J Med 2021; 53(2): 85-9.
- Open Access
- 29 October 2019
- Published by Politeknik Kementerian Kesehatan Banjarmasin in Medical Laboratory Technology Journal
Analysis between Adrenal MRI Mass Size and 1 mg Dexamethasone Suppression Test in Patients with Adrenal Incidentaloma
This study aimed to investigate the correlation of adrenal magnetic resonance imaging (MRI) mass size and 1 mg dexamethasone suppression test results in patients with adrenal incidentaloma diagnosis. Eighty-six patients (82.6% female) with incidentally discovered adrenal masses, diagnosed and treated in the Department of Endocrinology Bakirkoy Dr. Sadi Konuk Education and Research Hospital between June and August 2017, were included in the analysis. All the patients evaluated for their hormonal functionality. 24-h urinary excretion of cortisol did not correlate with tumor size. But there was a positive correlation between longer adrenal nodule diameter and metanephrine, and there was a negative correlation between shorter adrenal nodule diameter and renin levels. We found that smaller and clinically “silent” tumors often do not demonstrate subclinical hormonal activity.
- 29 October 2019
- Published by Politeknik Kementerian Kesehatan Banjarmasin in Medical Laboratory Technology Journal
Open AccessAnalysis between Adrenal MRI Mass Size and 1 mg Dexamethasone Suppression Test in Patients with Adrenal Incidentaloma
This study aimed to investigate the correlation of adrenal magnetic resonance imaging (MRI) mass size and 1 mg dexamethasone suppression test results in patients with adrenal incidentaloma diagnosis. Eighty-six patients (82.6% female) with incidentally discovered adrenal masses, diagnosed and treated in the Department of Endocrinology Bakirkoy Dr. Sadi Konuk Education and Research Hospital between June and August 2017, were included in the analysis. All the patients evaluated for their hormonal functionality. 24-h urinary excretion of cortisol did not correlate with tumor size. But there was a positive correlation between longer adrenal nodule diameter and metanephrine, and there was a negative correlation between shorter adrenal nodule diameter and renin levels. We found that smaller and clinically “silent” tumors often do not demonstrate subclinical hormonal activity.
- Open Access
- 1 September 2019
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 3 (53) , 16-20
Frequency and independent risk factors of sarcopenia in type 2 diabetes
Journal of Clinical Medicine of Kazakhstan
- 1 September 2019
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 3 (53) , 16-20
Open AccessFrequency and independent risk factors of sarcopenia in type 2 diabetes
Journal of Clinical Medicine of Kazakhstan
- Open Access
- 15 March 2019
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 4 (1) , 6-9
Assessment of relationship between serum magnesium and serum glucose levels and HOMA-IR in diabetic and prediabetic patients
Aim: In this study, we aimed to investigate the serum magnesium (Mg) levels in diabetic and prediabetic patients and its correlation with age, body-mass index, HOMA-IR, serum fasting glucose, HbA1c, and insulin levels.Methods: In this retrospective study, a total of 130 patients consisted of newly diagnosed prediabetes (Group PD) (n=63) and type 2 diabetes mellitus (Group D) (n=67) were included. Patients' age, body mass index, serum Mg, glucose and insulin, HOMA-IR and HbA1c were recorded. The prediabetes and type 2 diabetes diagnoses had been made according to WHO criteria at the time of diagnosis.Results: In group D, the mean Mg level (1.88 ± 0.17 mg/dl) was significantly lower than group PD (1.96 ± 0.17 mg/dl) (p = 0.007). Correlation analysis showed that there was a significant negative correlation between Mg and glucose (r = -0.390, p = 0.001) and HOMA-IR (r = -0.284; p = 0.022) in the group D. No correlation was found between serum Mg level and serum insulin, HbA1c, age, and body-mass index (p = 0.801, 0.087, 0.611 and 0.691, respectively). In group PD, serum insulin, HbA1c, glucose, HOMA-IR, age, and body-mass index were not corraleted with serum Mg levels (p = 0.801, 0.087, 0.939, 0.998, 0.611 and 0.691, respectively). Conclusıon: We showed that while there was a negative correlation between magnesium levels and HOMA-IR and fasting blood glucose levels in diabetic patients, but this correlation was not present in prediabetic patients. Our results suggest that serum Mg level is associated with metabolic control of type 2 diabetes and thus it can be considered in these patients.
- 15 March 2019
- Published by Archives of Clinical and Experimental Medicine in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
- Vol. 4 (1) , 6-9
Open AccessAssessment of relationship between serum magnesium and serum glucose levels and HOMA-IR in diabetic and prediabetic patients
Aim: In this study, we aimed to investigate the serum magnesium (Mg) levels in diabetic and prediabetic patients and its correlation with age, body-mass index, HOMA-IR, serum fasting glucose, HbA1c, and insulin levels.Methods: In this retrospective study, a total of 130 patients consisted of newly diagnosed prediabetes (Group PD) (n=63) and type 2 diabetes mellitus (Group D) (n=67) were included. Patients' age, body mass index, serum Mg, glucose and insulin, HOMA-IR and HbA1c were recorded. The prediabetes and type 2 diabetes diagnoses had been made according to WHO criteria at the time of diagnosis.Results: In group D, the mean Mg level (1.88 ± 0.17 mg/dl) was significantly lower than group PD (1.96 ± 0.17 mg/dl) (p = 0.007). Correlation analysis showed that there was a significant negative correlation between Mg and glucose (r = -0.390, p = 0.001) and HOMA-IR (r = -0.284; p = 0.022) in the group D. No correlation was found between serum Mg level and serum insulin, HbA1c, age, and body-mass index (p = 0.801, 0.087, 0.611 and 0.691, respectively). In group PD, serum insulin, HbA1c, glucose, HOMA-IR, age, and body-mass index were not corraleted with serum Mg levels (p = 0.801, 0.087, 0.939, 0.998, 0.611 and 0.691, respectively). Conclusıon: We showed that while there was a negative correlation between magnesium levels and HOMA-IR and fasting blood glucose levels in diabetic patients, but this correlation was not present in prediabetic patients. Our results suggest that serum Mg level is associated with metabolic control of type 2 diabetes and thus it can be considered in these patients.
- Open Access
- 3 January 2019
- Published by The European Research Journal in The European Research Journal
- Vol. 5 (1) , 14-19
The relationship between atrial natriuretic peptide and microvascular complications of diabetes
Objective: In this study, we aimed to determine the relationship between the atrial natriuretic peptide and microvascular complications of diabetes. Methods: Sixty patients with type 2 diabetes mellitus were enrolled into the study. Patients with a chronic disease other than diabetes mellitus were excluded from the study. The body-mass index, waist circumference, and hip circumference were measured and blood samples for routine biochemical tests were taken after at least 12 hours fasting. The microvascular complications of the patients were evaluated. Results: Thirty-two of the patients had microvascular complications whereas 28 of them did not. Age, body mass index, waist and hip circumference, and atrial natriuretic peptide levels were significantly higher in the group with microvascular complications than those without complications. There was no significant difference in parameters like; waist-hip ratio, blood glucose, HbA1c, fasting insulin, fasting HOMA, sodium, potassium, magnesium, calcium and lipid levels between the two groups. When the relationship between atrial natriuretic peptide and obesity, retinopathy, neuropathy, nephropathy, duration of diabetes, HbA1c, and sex are evaluated separately, the only significant parameters related to atrial natriuretic peptide were the body-mass index, waist circumference, hip circumference measurements, and neuropathy. Conclusions: Positive correlations between serum atrial natriuretic peptide levels and body-mass index, waist circumference, and hip circumference measurements were determined. Also, serum atrial natriuretic peptide levels were significantly higher in patients with obesity or neuropathy than those without obesity or neuropathy.
- 3 January 2019
- Published by The European Research Journal in The European Research Journal
- Vol. 5 (1) , 14-19
Open AccessThe relationship between atrial natriuretic peptide and microvascular complications of diabetes
Objective: In this study, we aimed to determine the relationship between the atrial natriuretic peptide and microvascular complications of diabetes. Methods: Sixty patients with type 2 diabetes mellitus were enrolled into the study. Patients with a chronic disease other than diabetes mellitus were excluded from the study. The body-mass index, waist circumference, and hip circumference were measured and blood samples for routine biochemical tests were taken after at least 12 hours fasting. The microvascular complications of the patients were evaluated. Results: Thirty-two of the patients had microvascular complications whereas 28 of them did not. Age, body mass index, waist and hip circumference, and atrial natriuretic peptide levels were significantly higher in the group with microvascular complications than those without complications. There was no significant difference in parameters like; waist-hip ratio, blood glucose, HbA1c, fasting insulin, fasting HOMA, sodium, potassium, magnesium, calcium and lipid levels between the two groups. When the relationship between atrial natriuretic peptide and obesity, retinopathy, neuropathy, nephropathy, duration of diabetes, HbA1c, and sex are evaluated separately, the only significant parameters related to atrial natriuretic peptide were the body-mass index, waist circumference, hip circumference measurements, and neuropathy. Conclusions: Positive correlations between serum atrial natriuretic peptide levels and body-mass index, waist circumference, and hip circumference measurements were determined. Also, serum atrial natriuretic peptide levels were significantly higher in patients with obesity or neuropathy than those without obesity or neuropathy.
- 1 June 2018
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 14 (Suppl 2) , S536-S537
Ventricular bigeminal rhythm associated with trastuzumab
Cardiac side effects of targeted chemotherapy agents are getting more and more important topic nowadays. However, the studies on this topic are limited. Because multiple agent chemotherapy is not a common treatment option, it is hard to establish controlled study groups (as before chemotherapy and after chemotherapy); further, cancer, itself, may cause cardiac side effects and uncertainty of the symptoms may be associated with previous clinical situation before chemotherapy. For all that, we may get information to a certain degree about the side effects of these agents by analyzing case reports. These side effects have a broad spectrum from asymptomatic rhythm alterations to acute cardiac death. In this case report, we aim to discuss asymptomatic ventricular bigeminal rhythm, which is proved by electrocardiography, of our patient during treated by trastuzumab.
- 1 June 2018
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 14 (Suppl 2) , S536-S537
Ventricular bigeminal rhythm associated with trastuzumab
Cardiac side effects of targeted chemotherapy agents are getting more and more important topic nowadays. However, the studies on this topic are limited. Because multiple agent chemotherapy is not a common treatment option, it is hard to establish controlled study groups (as before chemotherapy and after chemotherapy); further, cancer, itself, may cause cardiac side effects and uncertainty of the symptoms may be associated with previous clinical situation before chemotherapy. For all that, we may get information to a certain degree about the side effects of these agents by analyzing case reports. These side effects have a broad spectrum from asymptomatic rhythm alterations to acute cardiac death. In this case report, we aim to discuss asymptomatic ventricular bigeminal rhythm, which is proved by electrocardiography, of our patient during treated by trastuzumab.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 14 (Suppl 2) , S362-S367
Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC. Subjects and Methods: A total of 40 BC patients and 33 age-matched healthy women were included in this study. Beside other biochemical parameters, participants' serum PON and ARE levels were determined and analyzed. Results: Serum PON and ARE levels were found decreased in sera of the patients (96.44 ± 21 and 159.75 ± 15.75 U/L, respectively)compared to controls (158.39 ± 23.04 and 239.33 ± 32.98 U/L, respectively) (P = 0.001 for both). Subgroup analysis of the BC patients revealed that both serum PON and ARE levels were lower in patients who needed neoadjuvant chemotherapy (NAC), compared to those who did not (P = 0.024 and 0.02, respectively). We determined a cut-off value of PON according to the receiver operating characteristic curve analysis as 131.2 U/L (sensitivity 97.5% and specificity 93.9%). Conclusion: BC patients have lower serum PON and ARE levels than healthy controls. Also, serum ARE levels (but not PON) were negatively correlated with body mass index in BC patients. Both serum PON and ARE levels were lower in patients who needed NAC than in patients who did not need such therapy.
- 1 June 2018
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 14 (Suppl 2) , S362-S367
Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC. Subjects and Methods: A total of 40 BC patients and 33 age-matched healthy women were included in this study. Beside other biochemical parameters, participants' serum PON and ARE levels were determined and analyzed. Results: Serum PON and ARE levels were found decreased in sera of the patients (96.44 ± 21 and 159.75 ± 15.75 U/L, respectively)compared to controls (158.39 ± 23.04 and 239.33 ± 32.98 U/L, respectively) (P = 0.001 for both). Subgroup analysis of the BC patients revealed that both serum PON and ARE levels were lower in patients who needed neoadjuvant chemotherapy (NAC), compared to those who did not (P = 0.024 and 0.02, respectively). We determined a cut-off value of PON according to the receiver operating characteristic curve analysis as 131.2 U/L (sensitivity 97.5% and specificity 93.9%). Conclusion: BC patients have lower serum PON and ARE levels than healthy controls. Also, serum ARE levels (but not PON) were negatively correlated with body mass index in BC patients. Both serum PON and ARE levels were lower in patients who needed NAC than in patients who did not need such therapy.